[Perioperative Targeted Therapy for Operable, Early Stage NSCLC].

Autor: Etman S; Klinik für Thoraxchirurgie, Fachkrankenhaus Coswig GmbH, Coswig, Deutschland., Saalfeld F; Department of Oncology, Carl Gustav Carus University Hospital, Dresden, Germany., Aust D; Department of Pathology, Carl Gustav Carus University Hospital, Dresden, Germany., Sombati M; Klinik für Thoraxchirurgie, Fachkrankenhaus Coswig GmbH, Coswig, Deutschland., Decker R; Klinik für Thoraxchirurgie, Fachkrankenhaus Coswig GmbH, Coswig, Deutschland., Schweipert J; Department of Thoracic Surgery, Carl Gustav Carus University Hospital, Dresden, Germany., Baum D; Klinik für Thoraxchirurgie, Fachkrankenhaus Coswig GmbH, Coswig, Deutschland., Wermke M; Department of Oncology, Carl Gustav Carus University Hospital, Dresden, Germany., Ploenes T; Department of Thoracic Surgery, Carl Gustav Carus University Hospital, Dresden, Germany.; Klinik für Thoraxchirurgie, Fachkrankenhaus Coswig GmbH, Coswig, Deutschland.
Jazyk: němčina
Zdroj: Zentralblatt fur Chirurgie [Zentralbl Chir] 2024 Aug; Vol. 149 (S 01), pp. S45-S51. Date of Electronic Publication: 2024 Aug 13.
DOI: 10.1055/a-2353-0363
Abstrakt: Non-small cell lung cancer (NSCLC) is characterized by high recurrence rates in the early stages. In a German cohort, recurrence-free survival after 5 years was 62% (stage IA1), 40.7% (stage IIA) and 28% (stage IIIA). In addition to the perioperative use of immune checkpoint inhibitors, targeted tumor therapy is also making inroads as an innovation from the palliative setting into the early stages. Of particular relevance is the use of the EGFR inhibitor osimertinib, which has been shown to improve overall survival in the adjuvant setting. In this practice-oriented review, we briefly describe the current status of adjuvant targeted therapy and the associated testing and provide an outlook on further developments.
Competing Interests: Bezahlte Vorträge und Advisory Boards: MSD, AstraZeneca ; BMS, Novocure
(Thieme. All rights reserved.)
Databáze: MEDLINE